9.57
Schlusskurs vom Vortag:
$9.22
Offen:
$9.25
24-Stunden-Volumen:
800.94K
Relative Volume:
0.82
Marktkapitalisierung:
$617.03M
Einnahmen:
$202.09M
Nettoeinkommen (Verlust:
$-61.69M
KGV:
-8.8611
EPS:
-1.08
Netto-Cashflow:
$-35.64M
1W Leistung:
+3.24%
1M Leistung:
+3.13%
6M Leistung:
-32.27%
1J Leistung:
-22.26%
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Vergleichen Sie EOLS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
EOLS
Evolus Inc
|
9.57 | 597.69M | 202.09M | -61.69M | -35.64M | -1.08 |
![]()
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-17 | Eingeleitet | BTIG Research | Buy |
2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
2022-06-23 | Eingeleitet | Needham | Buy |
2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
2022-01-20 | Hochstufung | Truist | Hold → Buy |
2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
2021-02-24 | Herabstufung | Truist | Buy → Hold |
2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
2020-02-06 | Fortgesetzt | Mizuho | Buy |
2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
2019-09-05 | Fortgesetzt | Mizuho | Buy |
2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
2019-06-11 | Eingeleitet | Barclays | Underweight |
2019-03-20 | Eingeleitet | SunTrust | Buy |
2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Evolus Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com
Is Evolus Inc. a good long term investmentFree Risk Assessment Services - Autocar Professional
Evolus to Report Second Quarter Financial Results on August 5, 2025 - Yahoo Finance
What analysts say about Evolus Inc. stockFree Stock Selection - jammulinksnews.com
What drives Evolus Inc. stock priceFree Predictions - Autocar Professional
EvolusA Slightly Risky Buy Ahead Of Q2 Earnings (NASDAQ:EOLS) - Seeking Alpha
Midday Stock Roundup: loanDepot Up 10% with High Volume - Orange County Business Journal
How Evolus Inc. stock performs during market volatilityInsider Level Guidance - Newser
What makes Evolus Inc. stock price move sharplyTop Analyst Picks - Newser
Why Evolus Inc. stock attracts strong analyst attentionRisk Controlled Trading Ideas - Newser
Evolus announces inducement grants - Medical Buyer
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 - BioSpace
How reliable are EOLS's earnings forecasts historically? - AInvest
Is EOLS's Q1 2025 earnings forecast optimistic? - AInvest
Evolus Expands into French Market - Orange County Business Journal
EOLS Partners with Symatese for Nuceiva Distribution in France | - GuruFocus
Fastest-Growing Botox Alternative Nuceiva Enters French Beauty Market Through Strategic Partnership - Stock Titan
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France - Yahoo Finance
Trade Alert: President Of Evolus David Moatazedi Has Sold Stock - simplywall.st
Where are the Opportunities in (EOLS) - news.stocktradersdaily.com
When Can We Expect A Profit From Evolus, Inc. (NASDAQ:EOLS)? - Yahoo Finance
Evolus (NASDAQ:EOLS) Shares Down 5.5% on Insider Selling - Defense World
(EOLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS) - The Globe and Mail
Evolus Inc (EOLS) Stock Price Up 3.95% on Jun 11 - GuruFocus
Insider Spends US$189k Buying More Shares In Evolus - simplywall.st
Insider Buying: White Albert G III Acquires 20,000 Shares of Evolus Inc (EOLS) - GuruFocus
EOLS Director Boosts Stake with Significant Share Purchase | EOLS Stock News - GuruFocus
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):